Tempus IPO
Tempus is a precision medicine company that uses artificial intelligence and machine learning to analyze clinical and molecular data to help physicians make more informed treatment decisions for cancer and other diseases. The company combines genomic sequencing, clinical data, and AI to provide insights for personalized medicine. Investors are interested in Tempus due to the growing importance of precision medicine and the company's data-driven approach to healthcare.
What We Know
Tempus went public on NASDAQ in June 2024 under the ticker symbol TEM. The company raised approximately $411 million in its IPO, pricing shares at $37 each. The IPO was well-received by investors interested in the precision medicine and healthcare AI sectors. The company's public debut came after years of private funding and growth in the precision medicine space. Tempus has partnerships with major healthcare systems and pharmaceutical companies, and its IPO provided capital to further expand its platform and data capabilities. As a newly public company, Tempus is still establishing its track record in the public markets.
Frequently Asked Questions
Has Tempus had an IPO?
Yes, Tempus completed its IPO in June 2024 on NASDAQ. The company went public under the ticker symbol TEM, raising over $400 million in the offering.
When is the Tempus IPO date?
Tempus is already public, having completed its IPO in June 2024. There is no upcoming IPO date as the company recently began trading on NASDAQ.
How can I buy Tempus stock?
You can buy Tempus stock through any licensed brokerage account using the ticker symbol TEM on NASDAQ. The stock became available for trading following its IPO in June 2024.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts